Who is sponsoring NCT05402982?

NCT05402982 is sponsored by Ahmed Abdel Wahed Ali.

What drugs are being tested in NCT05402982?

Interventions in NCT05402982: Electrical Cardiometry (EC) ICON, Rohrich formula.

What condition does NCT05402982 study?

NCT05402982 studies Lipodystrophy.

Is NCT05402982 still recruiting?

NCT05402982 is currently completed. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT05402982

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intraoperative Fluid Management of Liposuction , Cardiometry Versus Rohrich Formula

Completed NA Last updated 29 November 2023

What this trial tests

NA trial testing Electrical Cardiometry (EC) ICON in Lipodystrophy in 50 participants. Completed in 1 July 2023.

Timeline

25 June 2022

Primary endpoint
10 June 2023

1 July 2023

Quick facts

Lead sponsor	Ahmed Abdel Wahed Ali
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	25 June 2022
Primary completion	10 June 2023
Estimated completion	1 July 2023
Sites	1 location across Egypt

Drugs / interventions tested

Electrical Cardiometry (EC) ICON
Rohrich formula

Conditions studied

Lipodystrophy — all drugs for Lipodystrophy →

Sponsor

Ahmed Abdel Wahed Ali

Who can join

Adults 21 to 60, any sex, with Lipodystrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to compare the hemodynamic parameters of fluid resuscitation using Rohrich formula to cardiometry guided stroke volume variation in patients undergoing large volume liposuction surgery .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lipodystrophy

Currently open trials in the same condition.

NCT05996536 — Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD) · recruiting
NCT06236932 — Susceptibility to Infectious Diseases in obEsity: an endocRine trAnslational socioLogic Evaluation, "SIDERALE" · NA · recruiting
NCT05789251 — Assess the Possibility of Diagnosing Diabetes and Rediabetes Following Oral Induced Hyperglycemia in Patients With Dunni · NA · recruiting
NCT05419037 — Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy · recruiting
NCT02262806 — Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05402982 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ahmed Abdel Wahed Ali
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05402982.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing